Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetirizine + QAV680
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cetirizine is a second-generation antihistamine used to relieve symptoms of allergic rhinitis (hay fever), perennial and seasonal allergies, urticaria (hives), and other allergic conditions. It works by blocking the action of histamine H1 receptor, thereby reducing allergy symptoms such as sneezing, itching, watery eyes, and runny nose. Cetirizine is widely marketed under the brand name Zyrtec[1][2][3][4]. QAV680 (also known as NVP-QAV680) is a pyrrolopyridine derivative developed by Novartis as an antagonist of the chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2 or DP2). It was investigated for inflammatory or obstructive airway diseases such as asthma and allergic rhinitis. QAV680 acts by selectively blocking prostaglandin D2 receptor 2 (CRTh2) involved in eosinophilic inflammation associated with these diseases[6][8]. The combination "cetirizine + QAV680" would theoretically target both histaminergic and prostaglandin D2-mediated pathways in allergy/inflammation.
- Other names
- cetirizineNvp-qav-680Nvp-qav680Nvp-qav 680QAV690 free acidQAV-690 free acidQAV 690 free acid
02
Targets
HRH1 (Histamine H1 Receptor)PTGDR2 (Prostaglandin D2 receptor 2)
Beyond the preview
Go deeper on cetirizine + QAV680.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetirizine + QAV680.